Biotechnology company PharmaGap Inc. today announced 80 percent average growth inhibition in in-vitro trials of its lead cancer drug GAP-107B8 in melanoma testing at Memorial Sloan-Kettering Cancer Center (MSKCC).

GAP-107B8 studies have demonstrated the drug as highly cytotoxic to numerous cancer types, including chemo-resistant cancers, in vitro.

PharmaGap said its test program at MSKCC will proceed to animal tests, with results expected during the third quarter. Animal testing will allow the company to research and identify various possibilities for the drug.

“We are seeing promising results in the melanoma cell line panel, and I am excited to be continuing with further testing, both in vitro and in animal models, to explore the potential for this new drug compound,” Dr. Gary Schwartz, chief of the Melanoma and Sarcoma Service at MSKCC stated in the press release.

GAP-107B8 was tested in cell proliferation assays in 6 Ocular Melanoma and 4 Cutaneous Melanoma human cancer cell lines, resulting in better understanding of GAP-107B8’s efficacy in slowing proliferation, its time course of effect in cells, dose level response patterns, and inhibition of known cell signaling targets. In all dose levels GAP107B8 showed a clear effect in slowing cancer cell proliferation.

The company said it will continue testing over the next few weeks with additional analysis and will continue to establish the safety profile of the drug.

“A series of tests are underway to provide the basis for selection of the cancer target for clinical trial application. I expect results from the pharmacokinetics program at the National Research Council, carried out in conjunction with Tandem Labs, to be available next week. I will be outlining the company’s program to licensing at the Annual General Meeting later today, and we will report further on that program in the next few days,” the company stated.

For more information visit www.pharmagap.com